TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Subcutaneous Mircera for the Treatment of Anemia in Peritoneal Dialysis Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* chronic kidney disease stage V;~* on peritoneal dialysis for 3 months prior to screening;~* on epoetin alfa sc \>=3 months prior to screening.~Exclusion Criteria:~* patients expecting to change dialysis modality over course of study;~* patients hospitalized during previous 3 months for any clinically significant condition;~* active malignancy;~* bleeding episode necessitating transfusion, or overt gastrointestinal bleeding within 3 months prior to screening;~* transfusion of red blood cells within 3 months prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RO0503821 (Type: EXPERIMENTAL): Eligible participants will be administered RO0503821 (methoxy polyethylene glycol-epoetin beta \[Mircera\]) subcutaneously (SC) every month for eight months (6 months of titration period \[TP\] and two months of evaluation period \[EP\] and 15-days following the final study visit (9 months post randomization). The first dose of Mircera (120, 200, or 360 mcg) will be based upon the dose of epoetin alfa received 1 to 2 weeks prior to administration of study drug, while subsequent doses will be adjusted to maintain haemoglobin (Hb) concentrations within target of \>=10.0 gram per decilitre (g/dL) and \<=12.0 g/dL. Participants who self-administered/visited to clinics for erythropoiesis stimulating agent (ESA) dosing prior to randomization will continue to do so.
- Epoetin Alfa (Type: ACTIVE_COMPARATOR): Eligible participants will be administered epoetin alfa SC as per the standard of care for eight months (TP and EP), and will be followed-up for 15 days following the final study visit. Participants who self-administered/visited to clinics for ESA dosing prior to randomization will continue to do so.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Rates DMBT1 ( Glycoprotein) in Sputum of CF Patients With Pseudomonas Aeruginosa

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* CF patient 6 years~* Availability of sputum~* Signed Informed consent~Exclusion Criteria:~* Cardiac insufficiency~* Anti-inflammatory drugs on going~* Oral corticosteroid therapy~* Inhaled corticosteroids during the two weeks before inclusion,~* Patient awaiting lung transplantation~* Patient with a past history of heart/lung transplantation~* Patient with a sputum examination positive for : atypical mycobacteria, Burkholderia cepacia, Stenotrophomonas maltophilia,~* Patient chronically colonized with multiresistant Pseudomonas aeruginosa~* Orkambi© or Kalydeco© therapy~* Change of the CF treatment during the last 4 weeks +/- 2 days before inclusion : corticosteroid, pancreatic extracts, antisecretory drugs...

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- group 1 (Type: None): CF patients with Pseudomonas aeruginosa chronic colonization.
- group 2 (Type: None): CF patients without a Pseudomonas aeruginosa chronic colonization.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~-Participants and Target Disease Characteristics- -~* Confirmed disease progression by RECIST 1.1 criteria on nivolumab maintenance after induction with ipilimumab and nivolumab~* Progress of maintenance treatment of nivolumab by RECIST. Pathology report must be submitted for embedded tissue block or tumor tissue.~Age and Reproduction Sexually active males with WOCBP must agree to instructions for contraception and fetal protection.~WOCBP need to use contraception throughout the study and for 5 months post treatment.~Exclusion Criteria autoimmune disease statement~* Active central nervous system metastases~* Participants with an active autoimmune disease, diabetes mellitus, skin disorders, hyperthyroidism requiring hormone treatments are permitted to enroll.~* Any major surgery 28 days before 1st treatment Concomitant Therapy~* participants that have received a live vaccine within 30 days of treatment.~* use of investigational agent or device with in 28 days before first dosage study treatment.~Physical and Laboratory Test Findings Allergies and Adverse Drug Reaction Age and Reproduction

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab + Ipilimumab (combination) (Type: EXPERIMENTAL): Nivolumab + Ipilimumab (combination) Q3W for 4 doses

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Alternate Day vs. Daily Iron Supplementation in Iron Depleted Women in the Philippines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female, 18 to 45 years old,~* SF levels \<25 µg/L,~* Hb levels 11-15.5 g/dL~* Normal Body Mass Index (18.5-25 kg/m2),~* In possession of a mobile phone on which the study app can be loaded~* Signed informed consent~Exclusion Criteria:~* Elevated CRP \> 5 mg/L~* Any metabolic, gastrointestinal, kidney or chronic disease such as diabetes, renal failure, hepatic dysfunction, hepatitis, hypertension, cancer or cardiovascular diseases (according to the participants own statement) affecting iron metabolism,~* Use of medication which may interfere with iron absorption, gut physiology and iron metabolism~* Consumption of iron supplements within 2 weeks prior to study start and of additional iron supplements during the study period~* Difficulties with blood sampling,~* Known hypersensitivity or allergy to iron or placebo capsules in the given amount (ferrous sulfate, mannitol, silica)~* Pregnancy, breastfeeding~* Known or suspected non-compliance, drug or alcohol abuse~* Cigarette smokers

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Consecutive Day Dosing (Type: ACTIVE_COMPARATOR): This arm will daily receive iron capsules for 3 months, followed by daily placebo capsules for 3 months.
- Alternate Day Dosing (Type: EXPERIMENTAL): This arm will receive iron capsules alternating with placebo capsules for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Impact of Personalized Coaching on the Time Period and Quality of Return to Work After Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Any patient active at the time of the diagnosis of breast cancer, treated consecutively at the Institut Curie during the study period, and whose first treatment will be surgery, will be offered participation in the study.~1. Invasive non-metastatic breast cancer, treated first by surgery~2. Age ≥ 18 and ≤ 60 years~3. Active woman at the time of diagnosis~4. Patient with internet access and email address~5. Patient affiliated with a social security scheme, speaking and reading French~6. Signature of informed consent~Exclusion Criteria:~1. In situ breast cancer~2. History of breast cancer~3. Metastatic breast cancer~4. Inflammatory Breast Cancer~5. Woman with a life expectancy \<6 months at the time of diagnosis (in relation to other serious chronic diseases)~6. Persons deprived of liberty or under guardianship~7. Impossibility to submit to the medical follow-up of the test for geographical, social or psychological reasons

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Intervention Group (Type: EXPERIMENTAL): intervention group that will receive return-to-work coaching sessions. The intervention consists of 3 individual coaching sessions with a certified professional coach. This personalized accompaniment will complete the standard accompaniment offered to all patients.
- Control Group (Type: NO_INTERVENTION): control group who will receive the current care which consists of a psychosocial care.~This care consists in offering the patient regular information meetings organized with social workers of the Health Insurance, to consult a psychologist and to access patients' homes at the frequency of their choice and according to their need.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Step Up For Health Study: A Pedometer and Website Intervention in Those With Prediabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* You are over 18 years of age.~* Have been told you have prediabetes by a health professional.~* You are free from any medical problems that make it hard to be active. For example, congestive heart failure, a recent knee or hip replacement, or you need to use a cane or walker to help you walk.~* Live in Alberta.~* Are interested in finding ways to become more physically active.~* Are interested in wearing a pedometer and tracking your daily steps.~Exclusion Criteria:~* You have been told you have type 2 diabetes.~* You do not confirm on the website that it is safe for you to increase your walking or other physical activities.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Website intervention (Type: EXPERIMENTAL): Website access: 12 Weekly emails, access to website with goal setting and recording steps
- Delayed access (Type: NO_INTERVENTION): Will not receive access to the program/website until they complete their 16 week assessments

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Cloxacillin and Fosfomycin Combination Versus Cloxacillin Monotherapy in Patients With MSSA Bacteremia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects, aged ≥ 18 years;~* MSSA bacteraemia: ≥ 1 positive blood culture(s) for MSSA in the first 72 h up to randomisation in patients with clinical suspicion of infection;~* Written informed consent of the participant or the legal representative.~Exclusion Criteria:~* Severe clinical status with expected death \<48h.~* Severe hepatic cirrhosis (Child-Pugh C).~* Moderate-severe cardiac chronic failure (NYHA III-IV).~* Prosthetic endocarditis (need for concomitant antibiotic therapy active against S. aureus together with the study antibiotics for the first 7 days of the study).~* No pre-existing evidence of S. aureus fosfomycin non-susceptibility.~* Known hypersensitivity to cloxacillin or fosfomycin.~* Polymicrobial bacteraemia with more than one microorganism in blood cultures.~* A positive pregnancy test or pregnancy or lactation at the time of inclusion.~* Miastenia gravis.~* Participation in another clinical trial.~* Previous participation in the present clinical trial.~* Acute SARS-CoV2 infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Combination therapy group (Type: EXPERIMENTAL): intravenous cloxacillin 2g/4h and fosfomycin 3 g/6h for the duration of 7 days treatment
- Standard therapy group (Type: ACTIVE_COMPARATOR): intravenous cloxacillin 2g/4h for the duration of 7 days IV treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Topical PH-10 Aqueous Hydrogel and Photodynamic Therapy for Psoriasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Stable, moderate to severe plaque psoriasis in at least three distinct plaque areas, each separated by at least a 2.5-cm band of normal skin. Study plaque areas, each covering a contiguous area up to 15 x 35 cm in size, should have a minimum plaque size of 2 cm2. All study plaque areas must be on the trunk or extremities (excluding palms, soles, scalp, and facial or intertriginous sites).~* Fitzpatrick skin type I-VI.~* Ability to understand and sign the informed consent document.~Exclusion Criteria:~* Female subjects of childbearing potential who are pregnant, attempting to conceive, or nursing an infant.~* Subjects who have received PUVA or UVB light therapy or systemic antipsoriatic therapy within 4 weeks of study treatment (two weeks for methotrexate).~* Subjects who have received topical antipsoriatic therapy (including corticosteroids, tar, anthralin, or Vitamin D analogs) to the study plaque areas within 2 weeks of study treatment.~* Subjects who have received any photosensitizing or phototoxic drug within 4 weeks of study treatment.~* Subjects who have received any approved biologic drug therapy for psoriasis within 3 months or 5 half-lives of study treatment.~* Subjects who have participated in a clinical research study within 4 weeks of study treatment.~* Subjects with a history of porphyria, systemic lupus erythematosus or xeroderma pigmentosum.~* Subjects with clinical conditions that, in the opinion of the Principal Investigator, may pose a health risk to the subject by being involved in the study or detrimentally affect regular follow-up of the subject.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Each subject's study plaque areas will be assigned by the investigator to two PH-10 treatment plaque areas and one control plaque area.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: First choIce Antidepressants: General Practitioner's Treatment Approach in the Czech Republic

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Signing of the Inform Consent Form (Personal Data Protection Consent included)~* Adults male and female newly diagnosed with depression in care of the general practitioner~Exclusion Criteria:~* Patients previously treated with depression or patients treated by a psychiatrist~* Pregnancy and breast-feeding~* Acute myocardial infarction~* Significant risk of suicide~* Concomitant antidepressant medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Glucocorticoid Antagonist Treatment for Tobacco Use Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male smokers aged 18 to 55 years;~* History of smoking at least 5 cigarettes daily for the past 12 months;~* In good health as verified by medical history, screening examination, and -screening laboratory tests~Exclusion Criteria:~* History of mifepristone allergy;~* Requirement of any form of regular psychotropic medication (antidepressants, antipsychotics, or anxiolytics) and recent psychiatric history (in the past 6 months);~* Medical illnesses including diabetes, cardiovascular, renal, endocrine, or hepatic disorders;~* Prolonged QTc interval \>450 msec;~* History of adrenal insufficiency or a morning plasma cortisol level less than 5 mcg/dl at screening;~* Hypokalemia at screening (defined as potassium level \< 3.5 mEq/L);~* Current use of clinically significant CYP 3A4 substrates including, simvastatin, lovastatin, cyclosporine, ergotamines, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, triazolam, midazolam.~* use of rifapentin, phenobarbital, phenytoin, carbamazepine, and St. John's Wort.~* Current use of strong 3A4 inhibitors including ketoconazole, itraconazole, nefazodone, ritonavir, nelfinavir, indinavir, atazanavir, amprenavir, fosamprenivir, boceprevir, clarithromycin, conivaptan, lopinavir, mibefradil, posaconazole, saquinavir, telaprevir, telithromycin, voriconazole.~* Treatment with systemic corticosteroids~* Current use of clinically significant CYP 3A inducers (e.g., rifampin, rifabutin);~* Abuse of alcohol or any other illicit or prescription drugs;~* Inability to tolerate cold exposure due to conditions such as peripheral -vascular disease or Raynaud's phenomenon;~* Inability to fulfill all scheduled visits and examination procedures throughout the study period.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Mifepristone (Type: ACTIVE_COMPARATOR): Mifepristone 600 mg/day in 2 tablets
- Placebo (Type: PLACEBO_COMPARATOR): matching placebo in 2 tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial and Cost Effectiveness Evaluation of Intra-arterial Thrombectomy in Acute Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 10\<=NIHSS Score=\<25~* Symptoms onset less than 4 hours~* Occlusion of the intracranial carotid, the middle cerebral artery (M1) or the upper third of the basilar~Exclusion Criteria:~* Contraindications for intravenous thrombolysis~* Occlusion or stenosis of the pre-occlusive cervical internal carotid artery ipsilateral to the lesion~* Any cause local prohibiting femoral catheterization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- IV thrombolysis + thrombectomy (Type: ACTIVE_COMPARATOR): None
- IV thrombolysis (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must have histologically confirmed multiple myeloma that is relapsed or refractory~* Patients may have had 1 or more prior chemotherapy regimens for multiple myeloma but none within the preceding 14 days~* Performance status (ECOG) ≤ 2~* Not pregnant or breastfeeding~Exclusion Criteria:~* Participants with a history of rapidly progressive disease \[increase in tumor size (≥ 50%) as defined by standard myeloma markers \], pelvic irradiation, chemotherapy or radiotherapy within the preceding 14 days~* Participants may not be receiving any other study agents within 21 days prior to entry on the study.~* The use of growth factors other than erythropoiesis stimulating agents or G-CSF (Neupogen or Neulasta) during the study period.~* Participants with evidence of active thromboembolic disease or a history of thromboembolism within the preceding 6 months (excluding thrombosis of a central line).~* Participants with a documented history of genetic predisposition for thrombosis (anti-phospholipid antibody syndrome, AT-III deficiency, etc.), platelet disorder or bleeding disorder.~* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.~* Individuals with a history of other malignancies are eligible only if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the preceding 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Migration Arm (Type: EXPERIMENTAL): Administration of eltrombopag to support platelets during chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues